- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Alzheimer’s disease drug development landscape ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2021 ; pages:1-9 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (11.11.2021), 1-9, 12.2021
- Creator
-
Bokhoven, Pieter van
Wilde, Arno de
Vermunt, Lisa
Leferink, Prisca S.
Heetveld, Sasja
Cummings, Jeffrey
Scheltens, Philip
Vijverberg, Everard G. B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00927-z
- URN
-
urn:nbn:de:101:1-2022012306503264363317
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bokhoven, Pieter van
- Wilde, Arno de
- Vermunt, Lisa
- Leferink, Prisca S.
- Heetveld, Sasja
- Cummings, Jeffrey
- Scheltens, Philip
- Vijverberg, Everard G. B.
- SpringerLink (Online service)
Other Objects (12)
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Non-drug Therapies for Alzheimer’s Disease: A Review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Non-drug Therapies for Alzheimer’s Disease: A Review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Alzheimer’s Disease Drug Development Pipeline 2020
Advances in Alzheimer’s Disease Drug Development
Geroscience and Alzheimer’s Disease Drug Development
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in Drug Therapy for Alzheimer’s Disease
The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs
Non-drug Therapies for Alzheimer’s Disease: A Review